Sudeep Pharma reported a 29.8% year-on-year increase in consolidated net profit for the first quarter of FY26, reaching ₹405.87 lakh. The Vadodara-based pharmaceutical company saw its total income from operations rise 26% to ₹1,637.16 lakh, driven by robust demand across its product portfolio. Standalone results mirrored this growth trajectory, with net profit climbing 34% to ₹338.29 lakh against a revenue backdrop of ₹1,154.84 lakh.

The Board of Directors approved the unaudited financial results at its meeting held on August 4, 2026. The results were reviewed by the Audit Committee and filed with the stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chairman and Managing Director Sujit Jaysukh Bhayani signed off on the financial statement, which is also available on the company’s website.

Financial Performance

The company’s consolidated earnings per share (EPS) stood at ₹3.59 for the quarter ended June 30, 2026, up from ₹2.84 in the corresponding period last year. Diluted EPS remained unchanged at ₹3.59. For the full fiscal year FY26, basic EPS was ₹15.50.

Standalone revenue from operations increased to ₹1,154.84 lakh from ₹867.94 lakh in Q1FY25. The standalone profit before tax rose to ₹454.08 lakh from ₹338.27 lakh, reflecting improved operational efficiency and cost management during the period.

What the Numbers Show

The divergence between standalone and consolidated profit growth highlights the contribution of subsidiaries or associates to the bottom line. While standalone profit grew by 34%, consolidated profit grew by 30%, suggesting that while core operations are expanding rapidly, associated entities may have faced margin pressures or lower growth rates compared to the previous quarter. The consistent rise in both top-line and bottom-line figures indicates sustained market demand for Sudeep Pharma’s offerings without significant one-time gains driving the result.

Sudeep Pharma Limited will host an earnings call with analysts and investors on Wednesday, August 5, 2026, at 11:00 AM IST. The conference is convened to discuss the company’s operational and financial performance for the quarter ended June 30, 2026 (Q1FY27). This event provides stakeholders with a direct channel to review the latest quarterly results and address queries regarding the company’s strategic direction in the pharmaceutical sector.

The announcement was made in compliance with Regulation 30 of the SEBI Listing Regulations, 2015. The notice was issued on July 27, 2026, by Dimple Mehta, Company Secretary & Compliance Officer of Sudeep Pharma Limited. The invitation includes access details for participants across India, the USA, the UK, Singapore, and Hong Kong, ensuring global investor accessibility.

Conference Call Details

Nuvama Wealth Management is hosting the conference call. Mr. Archit Joshi from Nuvama Wealth Management Ltd. will serve as the call leader. Participants can join via the following dial-in numbers:

Alternatively, investors may register and access the call via the link provided in the annexure of the original filing, which is also available on the company’s investor relations website.

Management Representation

The following senior executives from Sudeep Pharma Limited will represent the company during the call:

• Sujit Bhayani, Managing Director
• Shanil Bhayani, Director
• Ketan Vyas, Chief Financial Officer

What This Means for Investors

While the filing does not disclose specific financial figures such as net profit or revenue, the scheduling of this call confirms that Q1FY27 results have been finalized and are ready for dissemination. Investors should prepare questions regarding margin trends, order book status, and any operational updates relevant to the pharma sector. The absence of pre-disclosed metrics suggests that the primary source of data will be the live management commentary and any accompanying presentation materials shared during the event.